In the latest market updates, several notable upgrades and initiations have taken place among various companies.

DraftKings Inc. (Nasdaq: DKNG) received an upgrade from Neutral to Buy at UBS, with the price target raised from $19 to $30. This positive development has had a favorable impact on the pre-market trading of $DKNG, currently valued at $24.91, reflecting a rise of $0.80 (+3.32%).

Similarly, Azul S.A. (NYSE: AZUL) experienced an upgrade from Underperform to Neutral at BofA Securities, accompanied by a price target increase from $6.90 to $11. As a result, $AZUL is trading at $8.72 in pre-market, showing a gain of $0.32 (+3.81%).

TrueBlue, Inc. (NYSE: TBI) has also received an upgrade, shifting from Market Perform to Outperform at BMO Capital Markets. The price target for TrueBlue has been raised from $18 to $20. This upgrade has influenced the pre-market trading of $TBI, currently priced at $16.99, representing an increase of $0.95 (+5.92%).

Moving on to initiations, DICE Therapeutics, Inc. (Nasdaq: DICE) has been initiated with a Buy rating and a price target of $71 at Canaccord Genuity. Consequently, $DICE is trading at $33.35 in pre-market, exhibiting a rise of $0.69 (+2.11%).

Lastly, Progyny, Inc. (Nasdaq: PGNY) has also been initiated with a Buy rating, accompanied by a price target of $50 by BTIG Research. Pre-market trading for $PGNY stands at $37.89, showing a gain of $0.76 (+2.05%) following the initiation.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)